Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06453265 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Abuse Potential of Intranasal Cebranopadol
A Phase 1 study, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT06453265 is a Phase 1 study that has completed, run by Tris Pharma. The registered enrollment target is 48 participants.
The verdict
NCT06453265, a Phase 1 study, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users.
Interventions
- DRUG Treatment B
- DRUG Cebranopadol- 600 ug
- DRUG Cebranopadol- 800ug
- DRUG Cebranopadol- 1000ug
- DRUG Treatment A:
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-06-28 |
| Est. Completion | 2024-11-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06453265
The ClinicalTrials.gov registry entry for NCT06453265 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tris Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Treatment B is the first listed.
NCT06453265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06453265 about?
NCT06453265 is a clinical study titled "A Study to Assess the Abuse Potential of Intranasal Cebranopadol". The purpose of this study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users.
What is the current status of trial NCT06453265?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2024-06-28. Estimated completion is 2024-11-06.
What interventions are being tested in trial NCT06453265?
The interventions under investigation include: Treatment B (DRUG), Cebranopadol- 600 ug (DRUG), Cebranopadol- 800ug (DRUG), Cebranopadol- 1000ug (DRUG), Treatment A: (DRUG).
Who is sponsoring clinical trial NCT06453265?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.